BridgeBio Pharma (BBIO) Short-term Investments (2019 - 2026)

BridgeBio Pharma (BBIO) has 8 years of Short-term Investments data on file, last reported at $60.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments changed N/A year-over-year to $60.3 million; the trailing twelve-month figure through Mar 2026 stood at $60.3 million (changed N/A YoY), and the FY2025 full-year result was $17.4 million, changed N/A from the prior year.
• Short-term Investments rose to $60.3 million in Q1 2026, from $17.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $139.4 million in Q2 2024 to a low of $131000.0 in Q1 2024.
• A 5-year average of $35.5 million and a median of $30.9 million in 2023 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 21329.38% in 2022 and slumped 99.74% in 2024, its largest moves.
• Tracing BBIO's Short-term Investments over 5 years: stood at $37.9 million in 2022, then tumbled by 56.1% to $16.7 million in 2023, then soared by 737.14% to $139.4 million in 2024, then plunged by 87.55% to $17.4 million in 2025, then surged by 247.26% to $60.3 million in 2026.
• Business Quant data shows BBIO's Short-term Investments at $60.3 million in Q1 2026, $17.4 million in Q4 2025, and $3.0 million in Q3 2025.